Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22.053 patients

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Eklöf, J, Sørensen, R, Ingebrigtsen, TS, Sivapalan, P, Achir, I, Boel, JB, Bangsborg, J, Ostergaard, C, Dessau, RB, Jensen, US, Browatzki, A, Lapperre, TS, Janner, J, Weinreich, UM, Armbruster, K, Wilcke, T, Seersholm, N & Jensen, JUS 2019, 'Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22.053 patients' Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2019.06.011

APA

CBE

Eklöf J, Sørensen R, Ingebrigtsen TS, Sivapalan P, Achir I, Boel JB, Bangsborg J, Ostergaard C, Dessau RB, Jensen US, Browatzki A, Lapperre TS, Janner J, Weinreich UM, Armbruster K, Wilcke T, Seersholm N, Jensen JUS. 2019. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22.053 patients. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2019.06.011

MLA

Vancouver

Author

Eklöf, J ; Sørensen, R ; Ingebrigtsen, T S ; Sivapalan, P ; Achir, I ; Boel, J B ; Bangsborg, J ; Ostergaard, C ; Dessau, R B ; Jensen, U S ; Browatzki, A ; Lapperre, T S ; Janner, J ; Weinreich, U M ; Armbruster, K ; Wilcke, T ; Seersholm, N ; Jensen, J U S. / Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease : an observational cohort study of 22.053 patients. In: Clinical Microbiology and Infection. 2019.

Bibtex

@article{6df7e39ccf4a4dcd881dd7841fa95dc4,
title = "Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22.053 patients",
abstract = "OBJECTIVES: The role of Pseudomonas aeruginosa on long-term prognosis in COPD is unknown. The purpose of this study was to determine whether P. aeruginosa is associated with increased risk of exacerbations or death in patients with chronic obstructive pulmonary disease (COPD).METHODS: This is a multiregional epidemiological study based on complete data on COPD outpatients between 1 January 2010 and 31 October 2017 and corresponding microbiology and national register data. Time-dependent Cox proportional hazards models and propensity matching was used to estimate hospitalisation-demanding exacerbations and death after two years, separately and in combination.RESULTS: A total of 22.053 COPD outpatients were followed for a median of 1.082 days (interquartile-range: 427-1.862). P. aeruginosa was present in 905 (4.1{\%}) patients. During 730 days of follow-up, P. aeruginosa strongly and independently predicted an increased risk of hospitalisation for exacerbation or all-cause death (HR 2.8, 95{\%} CI 2.2-3.6; p<0.0001) and all-cause death (HR 2.7, 95{\%} CI 2.3-3.4; p<0.0001) in analyses adjusted for known and suspected confounders. The signal remained unchanged in unadjusted analyses as well as propensity-matched subgroup analyses. Among patients {"}ever-colonized{"} with P. aeruginosa, the incidence of hospital-demanding exacerbations doubled after the time of the first colonization.CONCLUSIONS: COPD patients with P. aeruginosa cultured from the airways had a markedly increased risk of exacerbations and death. It is still not clear whether this risk can be reduced by offering patients targeted antipseudomonal antibiotics. A randomised trial is currently recruiting patients to clarify this (ClinicalTrials.gov: NCT03262142).",
author = "J Ekl{\"o}f and R S{\o}rensen and Ingebrigtsen, {T S} and P Sivapalan and I Achir and Boel, {J B} and J Bangsborg and C Ostergaard and Dessau, {R B} and Jensen, {U S} and A Browatzki and Lapperre, {T S} and J Janner and Weinreich, {U M} and K Armbruster and T Wilcke and N Seersholm and Jensen, {J U S}",
note = "Copyright {\circledC} 2019. Published by Elsevier Ltd.",
year = "2019",
month = "6",
day = "22",
doi = "10.1016/j.cmi.2019.06.011",
language = "English",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Wiley-Blackwell Publishing Ltd",

}

RIS

TY - JOUR

T1 - Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease

T2 - an observational cohort study of 22.053 patients

AU - Eklöf, J

AU - Sørensen, R

AU - Ingebrigtsen, T S

AU - Sivapalan, P

AU - Achir, I

AU - Boel, J B

AU - Bangsborg, J

AU - Ostergaard, C

AU - Dessau, R B

AU - Jensen, U S

AU - Browatzki, A

AU - Lapperre, T S

AU - Janner, J

AU - Weinreich, U M

AU - Armbruster, K

AU - Wilcke, T

AU - Seersholm, N

AU - Jensen, J U S

N1 - Copyright © 2019. Published by Elsevier Ltd.

PY - 2019/6/22

Y1 - 2019/6/22

N2 - OBJECTIVES: The role of Pseudomonas aeruginosa on long-term prognosis in COPD is unknown. The purpose of this study was to determine whether P. aeruginosa is associated with increased risk of exacerbations or death in patients with chronic obstructive pulmonary disease (COPD).METHODS: This is a multiregional epidemiological study based on complete data on COPD outpatients between 1 January 2010 and 31 October 2017 and corresponding microbiology and national register data. Time-dependent Cox proportional hazards models and propensity matching was used to estimate hospitalisation-demanding exacerbations and death after two years, separately and in combination.RESULTS: A total of 22.053 COPD outpatients were followed for a median of 1.082 days (interquartile-range: 427-1.862). P. aeruginosa was present in 905 (4.1%) patients. During 730 days of follow-up, P. aeruginosa strongly and independently predicted an increased risk of hospitalisation for exacerbation or all-cause death (HR 2.8, 95% CI 2.2-3.6; p<0.0001) and all-cause death (HR 2.7, 95% CI 2.3-3.4; p<0.0001) in analyses adjusted for known and suspected confounders. The signal remained unchanged in unadjusted analyses as well as propensity-matched subgroup analyses. Among patients "ever-colonized" with P. aeruginosa, the incidence of hospital-demanding exacerbations doubled after the time of the first colonization.CONCLUSIONS: COPD patients with P. aeruginosa cultured from the airways had a markedly increased risk of exacerbations and death. It is still not clear whether this risk can be reduced by offering patients targeted antipseudomonal antibiotics. A randomised trial is currently recruiting patients to clarify this (ClinicalTrials.gov: NCT03262142).

AB - OBJECTIVES: The role of Pseudomonas aeruginosa on long-term prognosis in COPD is unknown. The purpose of this study was to determine whether P. aeruginosa is associated with increased risk of exacerbations or death in patients with chronic obstructive pulmonary disease (COPD).METHODS: This is a multiregional epidemiological study based on complete data on COPD outpatients between 1 January 2010 and 31 October 2017 and corresponding microbiology and national register data. Time-dependent Cox proportional hazards models and propensity matching was used to estimate hospitalisation-demanding exacerbations and death after two years, separately and in combination.RESULTS: A total of 22.053 COPD outpatients were followed for a median of 1.082 days (interquartile-range: 427-1.862). P. aeruginosa was present in 905 (4.1%) patients. During 730 days of follow-up, P. aeruginosa strongly and independently predicted an increased risk of hospitalisation for exacerbation or all-cause death (HR 2.8, 95% CI 2.2-3.6; p<0.0001) and all-cause death (HR 2.7, 95% CI 2.3-3.4; p<0.0001) in analyses adjusted for known and suspected confounders. The signal remained unchanged in unadjusted analyses as well as propensity-matched subgroup analyses. Among patients "ever-colonized" with P. aeruginosa, the incidence of hospital-demanding exacerbations doubled after the time of the first colonization.CONCLUSIONS: COPD patients with P. aeruginosa cultured from the airways had a markedly increased risk of exacerbations and death. It is still not clear whether this risk can be reduced by offering patients targeted antipseudomonal antibiotics. A randomised trial is currently recruiting patients to clarify this (ClinicalTrials.gov: NCT03262142).

U2 - 10.1016/j.cmi.2019.06.011

DO - 10.1016/j.cmi.2019.06.011

M3 - Journal article

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

ER -

ID: 57456165